Literature DB >> 22243729

Infliximab as a steroid-sparing agent in refractory cutaneous sarcoidosis: single-center retrospective study of 9 patients.

Thomas Sené, Caroline Juillard, Michel Rybojad, Florence Cordoliani, Céleste Lebbé, Patrice Morel, Abdellatif Tazi, Fabien Guibal.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22243729     DOI： 10.1016/j.jaad.2011.05.040

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  4 in total

Review 1.  [Cutaneous manifestations of sarcoidosis].

Authors:  K Amschler; C S Seitz
Journal:  Z Rheumatol       Date:  2017-06       Impact factor: 1.372

2.  Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases.

Authors:  Valentine Heidelberger; Saskia Ingen-Housz-Oro; Alicia Marquet; Matthieu Mahevas; Didier Bessis; Laurence Bouillet; Frédéric Caux; Catherine Chapelon-Abric; Sébastien Debarbieux; Emmanuel Delaporte; Anne-Bénédicte Duval-Modeste; Olivier Fain; Pascal Joly; Sylvain Marchand-Adam; Jean-Benoît Monfort; Nicolas Noël; Thierry Passeron; Marc Ruivard; Françoise Sarrot-Reynauld; Denis Verrot; Diane Bouvry; Laurence Fardet; Olivier Chosidow; Pascal Sève; Dominique Valeyre
Journal:  JAMA Dermatol       Date:  2017-07-01       Impact factor: 10.282

3.  A case series of refractory cutaneous sarcoidosis successfully treated with infliximab.

Authors:  Papapit Tuchinda; Matthew Bremmer; Anthony A Gaspari
Journal:  Dermatol Ther (Heidelb)       Date:  2012-07-26

4.  Biologics in dermatology.

Authors:  David Chandler; Anthony Bewley
Journal:  Pharmaceuticals (Basel)       Date:  2013-04-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.